Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

protagonist therapeutics inc - PTGX

PTGX

Close Chg Chg %
145.87 4.13 2.83%

Pre-Market

150.00

+4.13 (2.83%)

Volume: 545.97K

Last Updated:

Aug 10, 2026, 4:00 PM EDT

Trade Now

Company Overview: protagonist therapeutics inc - PTGX

PTGX Key Data

Open

$149.26

 Day Range

147.40 - 151.50

52 Week Range

50.58 - 151.50

 Market Cap

$8.51B

Shares Outstanding

64.31M

 Public Float

61.03M

Beta

1.78

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.80

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

552.73K

  

PTGX Performance

1 Week
 
 0.00%
 
1 Month
 
 11.00%
 
3 Months
 
 46.81%
 
1 Year
 
 185.63%
 
5 Years
 
 205.87%
 

PTGX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 13
Full Ratings ➔

About protagonist therapeutics inc - PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

PTGX At a Glance

Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Newark, California 94560-1160
Phone 1-510-474-0170 Revenue 46.02M
Industry Pharmaceuticals: Major Net Income -130,149,000.00
Sector Health Technology Employees 132
Fiscal Year-end 12 / 2026
View SEC Filings

PTGX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 120.664
Price to Book Ratio 8.891
Price to Cash Flow Ratio 96.28
Enterprise Value to EBITDA -31.838
Enterprise Value to Sales 108.559
Total Debt to Enterprise Value 0.002

PTGX Efficiency

Revenue/Employee 348,606.061
Income Per Employee -985,977.273
Receivables Turnover 10.235
Total Asset Turnover 0.065

PTGX Liquidity

Current Ratio 12.71
Quick Ratio 12.71
Cash Ratio 12.486

PTGX Profitability

Gross Margin 97.338
Operating Margin -343.635
Pretax Margin -281.013
Net Margin -282.834
Return on Assets -18.373
Return on Equity -20.178
Return on Total Capital -20.823
Return on Invested Capital -19.894

PTGX Capital Structure

Total Debt to Total Equity 1.679
Total Debt to Total Capital 1.652
Total Debt to Total Assets 1.541
Long-Term Debt to Equity 1.308
Long-Term Debt to Total Capital 1.286
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Protagonist Therapeutics Inc - PTGX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
26.58M 60.00M 434.43M 46.02M
Sales Growth
-2.84% +125.73% +624.06% -89.41%
Cost of Goods Sold (COGS) incl D&A
1.03M 3.31M 2.96M 1.23M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.03M 3.31M 2.96M 1.23M
Depreciation
1.03M 3.31M 2.96M 1.23M
Amortization of Intangibles
- - - -
-
COGS Growth
-62.81% +220.93% -10.54% -58.66%
Gross Income
25.55M 56.69M 431.47M 44.79M
Gross Income Growth
+3.93% +121.88% +661.13% -89.62%
Gross Profit Margin
+96.12% +94.48% +99.32% +97.34%
2022 2023 2024 2025 5-year trend
SG&A Expense
156.92M 150.34M 178.63M 202.92M
Research & Development
126.22M 120.16M 138.13M 159.29M
Other SG&A
30.71M 30.18M 40.50M 43.63M
SGA Growth
+2.21% -4.19% +18.82% +13.60%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(131.37M) (93.65M) 252.84M (158.13M)
Non Operating Income/Expense
3.98M 14.70M 26.57M 28.82M
Non-Operating Interest Income
4.06M 14.90M 26.32M 28.79M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(127.39M) (78.95M) 279.41M (129.31M)
Pretax Income Growth
+0.98% +38.02% +453.88% -146.28%
Pretax Margin
-479.26% -131.59% +64.32% -281.01%
Income Tax
- - 4.22M 838.00K
-
Income Tax - Current - Domestic
- - 4.22M 838.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(127.39M) (78.95M) 275.19M (130.15M)
Minority Interest Expense
- - - -
-
Net Income
(127.39M) (78.95M) 275.19M (130.15M)
Net Income Growth
-1.47% +38.02% +448.54% -147.29%
Net Margin Growth
-479.26% -131.59% +63.34% -282.83%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(127.39M) (78.95M) 275.19M (130.15M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(127.39M) (78.95M) 275.19M (130.15M)
EPS (Basic)
-2.5976 -1.3909 4.4697 -2.0472
EPS (Basic) Growth
+4.16% +46.45% +421.35% -145.80%
Basic Shares Outstanding
49.04M 56.76M 61.57M 63.57M
EPS (Diluted)
-2.5976 -1.3909 4.2286 -2.0472
EPS (Diluted) Growth
+4.16% +46.45% +404.02% -148.41%
Diluted Shares Outstanding
49.04M 56.76M 65.08M 63.57M
EBITDA
(130.34M) (90.34M) 255.81M (156.90M)
EBITDA Growth
-3.31% +30.69% +383.16% -161.34%
EBITDA Margin
-490.35% -150.57% +58.88% -340.97%

Snapshot

Average Recommendation BUY Average Target Price 133.769
Number of Ratings 13 Current Quarters Estimate 2.018
FY Report Date 09 / 2026 Current Year's Estimate 4.227
Last Quarter’s Earnings 2.18 Median PE on CY Estimate N/A
Year Ago Earnings -2.05 Next Fiscal Year Estimate -0.502
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 13 12
Mean Estimate 2.02 0.21 4.23 -0.50
High Estimates 3.60 2.88 5.64 3.70
Low Estimate -0.80 -0.80 2.05 -2.75
Coefficient of Variance 77.60 599.27 24.04 -394.05

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 12
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Protagonist Therapeutics Inc - PTGX

Date Name Shares Transaction Value
Jan 8, 2026 Arturo Molina Chief Medical Officer 106,780 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Arturo Molina Chief Medical Officer 32,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Lewis T. Williams Director 7,825 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Lewis T. Williams Director 3,762 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Harold E. Selick Director 46,546 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Harold E. Selick Director 3,762 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Dinesh V. Patel President and CEO; Director 614,943 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Dinesh V. Patel President and CEO; Director 120,200 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Sarah A. O'Dowd Director 7,825 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Sarah A. O'Dowd Director 3,762 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 William D. Waddill Director 7,825 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 William D. Waddill Director 3,762 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Bryan Giraudo Director 17,825 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Bryan Giraudo Director 3,762 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Asif Ali Chief Financial Officer 86,665 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Asif Ali Chief Financial Officer 32,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Protagonist Therapeutics Inc in the News